Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children

Journal of Infectious Diseases

Volumn 204, Issue 1, 2011, Pages 9-18

  Bejon, Philip ^a,c   Cook, Jackie ^b   Bergmann Leitner, Elke ^e   Olotu, Ally ^a   Lusingu, John ^h,k   Mwacharo, Jedidah ^a   Vekemans, Johan ⁱ   Njuguna, Patricia ^a   Leach, Amanda ⁱ   Lievens, Marc ⁱ   Dutta, Sheetij ^e   Von Seidlein, Lorenz ^b,j   Savarese, Barbara ^f   Villafana, Tonya ^f,g   Lemnge, Martha M ^h   Cohen, Joe ⁱ   Marsh, Kevin ^a,c   Corran, Patrick H ^b,d   Angov, Evelina ^e   Riley, Eleanor M ^b   Drakeley, Chris J ^b   more..

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f PATH Malaria Vaccine Initiative   (United States)

^g MEDIMMUNE   (United States)

^h NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^j MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; EBA 175; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; IMMUNITY; INFECTION RISK; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ANTIBODIES, PROTOZOAN; CHILD, PRESCHOOL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFANT; LONGITUDINAL STUDIES; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RISK FACTORS;

EID: 79957962313     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir222     Document Type: Article

References (50)

1. Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008; 5:e38.
2. Okiro EA, Hay SI, Gikandi PW, et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar J 2007; 6:151.
3. Global Malaria Program Surveillance Monitoring and Evaluation Unit. Impact of long-lasting insecticidal-treated nets (LLINs) and artemisinin-based combination therapies (ACTs) measured using surveillance data, in four African countries; Preliminary report based on four country visits. Geneva, Switzerland: World Health Organization, 2008.
4. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007; 4:e309.
5. Garcon N, Heppner DG, Cohen J. Development of RTS, S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2003; 2:231-8.
6. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411-20.
7. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521-32.
8. Moorthy VS, Ballou WR. Immunological mechanisms underlying protection mediated by RTS, S: a review of the available data. Malar J 2009; 8:312.
9. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008; 9:725-32. (Pubitemid 351859155)
10. Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005; 191:619-26. (Pubitemid 40216679)
11. Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002; 360:610-7. (Pubitemid 35232195)
12. Bejon P, Ogada E, Peshu N, Marsh K. Interactions between age and ITN use determine the risk of febrile malaria in children. PLoS One 2009; 4:e8321.
13. Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol 2008; 24:578-84.
14. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: a systematic review and meta-analysis. PLoS Med 2010; 7:e1000218.
15. Corran PH, Cook J, Lynch C, et al. Dried blood spots as a source of antimalarial antibodies for epidemiological studies. Malar J 2008; 7:195.
16. Angov E, Aufiero BM, Turgeon AM, et al. Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine. Mol Biochem Parasitol 2003; 128:195-204.
17. Tsai CW, Duggan PF, Jin AJ, et al. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Mol Biochem Parasitol 2009; 164:45-56.
18. Zhang D, Pan W. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites. Infect Immun 2005; 73:6530-6. (Pubitemid 41368817)
19. Dutta S, Lalitha PV, Ware LA, et al. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 2002; 70:3101-10. (Pubitemid 34564173)
20. Bergmann-Leitner ES, Duncan EH, Mullen GE, et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg 2006; 75:437-42. (Pubitemid 46941302)
21. Bergmann-Leitner ES, Duncan EH, Burge JR, Spring M, Angov E. Short report: Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials. Am J Trop Med Hyg 2008; 78:468-71. (Pubitemid 351845199)
22. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Statist 1994; 43:429-67.
23. Armitage P, Berry G, Matthews J. Using STATA's robust cluster command as appropriate.. Statistical Methods in Medical Research, 4th ed. Oxford: Blackwell Scientific Publications, 2001.
24. Kulldorff M. SaTScan - Software for the spatial, temporal, and space-time scan statistics. http://www.satscan.org/. Information Management Services, 2010.
25. Kulldorff M, Heffernan R, Hartman J, Assuncao R, Mostashari F. A space-time permutation scan statistic for disease outbreak detection. PLoS Med 2005; 2:e59.
26. Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 1998; 58:406-13. (Pubitemid 28183248)
27. Bejon P, Warimwe G, Mackintosh CL, et al. Immunity. to febrile malaria in children: an analysis that distinguishes immunity from lack of exposure. Infect Immun 2009; 77:1917-23.
28. Lengeler C. Insecticide-treated bednets and curtains for preventing malaria (Cochrane Review). Cochrane Database Syst Rev 2004, CD000363.
29. Dent AE, Bergmann-Leitner ES, Wilson DW, et al. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One 2008; 3:e3557.
30. McCallum FJ, Persson KE, Mugyenyi CK, et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 2008; 3:e3571.
31. Sacarlal J, Aide P, Aponte JJ, et al. Long-term safety and efficacy of the RTS, S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009; 200:329-36.
32. Guinovart C, Aponte JJ, Sacarlal J, et al. Insights into long-lasting protection induced by RTS, S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS One 2009; 4:e5165.
33. Sama W, Killeen G, Smith T. Estimating the duration of Plasmodium falciparum infection from trials of indoor residual spraying. Am J Trop Med Hyg 2004; 70:625-34. (Pubitemid 38802391)
34. Kreuels B, Kobbe R, Adjei S, et al. Spatial variation of malaria incidence in young children from a geographically homogeneous area with high endemicity. J Infect Dis 2008; 197:85-93. (Pubitemid 351263471)
35. Belizario VY, Saul A, Bustos MD, et al. Field epidemiological studies on malaria in a low endemic area in the Philippines. Acta Trop 1997; 63:241-56. (Pubitemid 27141752)
36. Gaudart J, Poudiougou B, Dicko A, et al. Space-time clustering of childhood malaria at the household level: a dynamic cohort in a Mali village. BMC Public Health 2006; 6:286.
37. Bousema T, Drakeley C, Gesase S, et al. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 2010; 201:1764-74.
38. Snow RW, Omumbo JA, Lowe B, et al. Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet 1997; 349:1650-4. (Pubitemid 27234806)
39. Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011; 11:102-9.
40. Corran PH, O'Donnell RA, Todd J, et al. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun 2004; 72:6185-9. (Pubitemid 39303741)
41. Nwuba RI, Sodeinde O, Anumudu CI, et al. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun 2002; 70:5328-31.
42. Takala SL, Coulibaly D, Thera MA, et al. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med 2007; 4:e93.
43. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J ExpMed 1990; 172:1633-41.
44. Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 1992; 60:1473-81.
45. Achtman AH, Stephens R, Cadman ET, Harrison V, Langhorne J. Malaria-specific antibody responses and parasite persistence after infection of mice with Plasmodium chabaudi chabaudi. Parasite Immunol 2007; 29:435-44. (Pubitemid 47313227)
46. Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008; 76:2240-8. (Pubitemid 351656161)
47. Nebie I, Diarra A, Ouedraogo A, et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 2008; 76:759-66. (Pubitemid 351251748)
48. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 2010; 107:6958-63.
49. Drakeley CJ, Corran PH, Coleman PG, et al. Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A 2005; 102:5108-13.
50. Gray JC, Corran PH, Mangia E, et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem 2007; 53:1244-53. (Pubitemid 47020980)